Upcoming CDD Webinar: PROTAC — Developing New Therapies through Targeted Protein Degradation

CDD Vault Webinar Logo

Upcoming CDD Webinar: PROTAC — Developing New Therapies through Targeted Protein Degradation

March 11, 2020  •  9:00AM (PT), 12:00PM (ET), 16:00 (GMT)

Traditional drug discovery pipelines have focused on inhibiting protein action to rebalance a disease state. This focus on protein inhibition has limited drug discovery potentially based on the ability of proteins to be targeted and which sites can lead to activity inhibition.

PROteolysis TArgeting Chimera (PROTACs) offer a new avenue for targeting disease states and expanding what diseases are druggable. PROTACs take advantage of the natural machinery of the cell to degrade proteins instead of simply inhibiting their activity. Researchers are using PROTACs to look beyond the active sites of proteins and expand their toolkit for drugging diseases.

Join CDD and our panel of experts as we take a look at the promise of PROTACs just as the first PROTACs are going through clinical trials!

Featuring these leading scientists...

Andy Phillips portrait

Andy Phillips, Ph.D.

President and CEO, C4 Therapeutics

Dr. Phillips joined C4 Therapeutics in the role of Chief Scientific Officer in January 2016 and also assumed the position of President and Chief Executive Officer in May 2018. Prior to joining C4 Therapeutics, Andy was Senior Director, Center for Development of Therapeutics at Broad Institute of MIT and Harvard, where he led overall therapeutic efforts and provided strategic leadership for a number of major partnerships. Previously, he was a Full Professor of Chemistry at Yale University and a Full Professor of Chemistry and Biochemistry at the University of Colorado. His research and accomplishments have been recognized by a number of awards including the ACS Cope Scholar Award. Andy holds a Ph.D. in Biochemistry and Chemistry from the University of Canterbury.

Eric Fischer portrait

Eric Fischer, Ph.D.

Assistant Professor, Harvard Medical School

Dr. Fischer is an Assistant Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Dana-Farber Cancer Institute. He co-directs the DFCI Center for Protein Degradation. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His lab pursues novel avenues of therapeutic intervention based on targeting components of the ubiquitin proteasome system, such as methods of targeted protein degradation. Dr. Fischer has been recognized for his pioneering work on the structure of cereblon, the mechanism of action of thalidomide, and his contributions to targeted protein degradation.

Nathanael Gray portrait

Nathanael Gray, Ph.D.

Professor, Harvard Medical School

Dr. Gray is the Nancy-Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Dana Farber Cancer Institute. Nathanael leads the Dana Farber Program in Chemical Biology and manages a research laboratory. Previously, Nathanael was the Director of Biological Chemistry at the Novartis Institute for Genomics (GNF) in San Diego where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs including ceritinib, siponimod and ABL001. Dr. Gray received his PhD in organic chemistry from Professor Peter Schultz at the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995.